Progenics - Die Zahlen - 500 Beiträge pro Seite

[Xedi]

Progenics Pharmaceuticals Reports First Quarter 2001 Endet den Dienstag, den 15. Mai, 2001 05:06:14 BIN - PR Newswire

TARRYTOWN, N.Y., der 15. Mai, 2001 /PRNewswire über COMTEX/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) heute bekanntgegeben seine Ergebnisse von Operationen für das beendete Viertel der 31. März 2001.

(Logo: www.newscom.com /cgi-bin/prnh/20010410/PROGENICS )

Einkünfte für das Viertel beendeten den 31. März, 2001 zählte $5.8 zusammen eine Million verglichen mit Einkünften von $3.4 eine Million für den gleichen Zeitraum 2000. Einkünfte daß man hauptsächlich Zahlungen widerspiegelt,
von der Gesellschaft unter seiner kürzlich beendeten Kollaboration mit Bristol-Myers Squibb Company und seiner an-gehenden Kollaboration mit F Hoffmann empfangen-La Roche-GmbH und Finanzierung von Regierungssubventionen und Verträgen. Die Kosten der Gesellschaft für das erste Viertel von 2001 waren $5.4 eine Million, verglich mit $4.8 eine Million für das erste Viertel von 2000. Nettoeinkommen da das erste Viertel von 2001 $461,000 war, verglich mit einem netto Verlust von ($1.5 eine Million) für den gleichen Zeitraum 2000. Das Nettoeinkommen pro teilen da das erste Viertel von 2001 $0.04 war, basisch und verdünntes $0.03, verglich mit einem netto Verlust pro Anteil von ($0.12), basisch und verdünnte für den gleichen Zeitraum von 2000. am Ende des ersten Viertels von 2001, hatte Progenics $57.0 eine Million in Bargeld, Bargeldgegenstücken und verkäuflichen mit $60.4 verglichenen Sicherheiten eine Million am 31. Dezember 2000.

Progenics Pharmaceuticals, Inc., von Tarrytown, NY, konzentriert eine biopharmazeutische Gesellschaft sich auf die Entwicklung und Kommerzialisierung von Erzeugnissen für die Behandlung und Verhinderung von viral, Krebs, und andere life-drohende Krankheiten.
Die Gesellschaft wendet seine immunological Sachkenntnisse an Bioarzneimittel zu entwickeln um Viruskrankheiten zu bekämpfen, wie menschliches immunodeficiency-Virus (HIV) Infektionen, und Krebse, wie bösartiges melanoma und Prostatakrebs. Die Gesellschaft hat initiiert II klinische Prozesse von seinem Blei-HIV-Erzeugnis, PROFI 542, einem viral-Eintritts inhibitor, schrittweise Durchführen. Die Gesellschaft entwickelt folg-an Erzeugniskandidaten in HIV-Infektion: PROFI 367 hat eine Phase abgeschlossen, die ich studiere, PROFI 140 bereitet sich darauf vor, Phasen-I/II-Prozesse, und ein Blei anzufangen, therapeutischer Kandidat ist von einer neuartigen Klasse von als sulfated-CCR5-peptides bekannten Anti-HIV-Zusammensetzungen gewählt worden. Die Gesellschaft ist auch mit Programmen beschäftigt, um Kleinmolekül-HIV-therapeutics, die man die Fusionscoempfänger des Virus und andere Programme als Zielgruppe hat, als man sich auf HIV-Anfügung und Fusion konzentriert, Kleinmolekül-HIV-therapeutics zu entdecken, die die Fusionscoempfänger des Virus und andere Programme als Zielgruppe haben, die sich auf HIV-Anfügung und Fusion konzentrieren, die man die Fusionscoempfänger des Virus und andere Programme als Zielgruppe hat, als man sich auf HIV-Anfügung und Fusion konzentriert, und zu entwickeln, die die Fusionscoempfänger des Virus und andere Programme als Zielgruppe haben, die sich auf HIV-Anfügung und Fusion konzentrieren. Die Gesellschaft entwickelt auf PSMA basierte Krebs-immunotherapies (Prostataspezifischmembranantigen) Technologie.
Das am meisten klinisch vorgesetzte Erzeugnis der Gesellschaft, GMK, ist ein Krebsimpfstoff in Phase III klinische Prozesse für die Behandlung von bösartigem melanoma. Progenics entwickelt auch einen zweiten Krebsimpfstoff, MGV, mit breiter Anwendung zu einer Vielfalt von Krebsen. Die Gesellschaft entwickelt auch ein neuartiges Kleinmolekül-antioxidant, dehydroascorbic-Säure (DHA), um Schlag und andere Unordnung zu behandeln.


PROGENICS-ARZNEIMITTEL, INC. KOMPRIMIERT AUSSAGEN VON OPERATIONEN Drei Monate Beendeten den 31. März, 2001 2000 (Unaudited) (Unaudited) Vertrags-Forschung und Entwicklung, Subventionen und Erzeugnis Abschlüsse-$4,942,305-$2,346,474-Interessen-Einkommen 904,479 1,027,773 Zählen Einkünfte 5,846,784 Zusammen 3,374,247 Forschung und Entwicklungskosten 3,731,045 3,457,781 Allgemein und administrativ 1,058,113 996,376 Verlust in Verbundvorhaben 418,020 187,913 Interessen-Kosten 12,080 22,499 Abschreibung und Amortisation 166,277 181,645 Gesamtkosten 5,385,535 4,846,214 Nettoeinkommen (Verlust) $461,249 $(1,471,967) Nettoeinkommen (Verlust) pro Anteil - basisch $0.04 $(0.12) Nettoeinkommen (Verlust) pro Anteil - verdünnt $0.03 $(0.12) Belastet den Durchschnitt ermitteln Gemeinsamkeit Anteile hervorragend - basisch 12,313,035 12,029,069 Belastet den Durchschnitt ermitteln Gemeinsamkeit Anteile hervorragend - verdünnt 13,914,386 12,029,069 KOMPRIMIERT BILANZEN der 31. März, der 31. Dezember, 2001 2000 (Unaudited) (Unaudited) Bargeld, Bargeldgegenstücke und verkäuflich ausstehende Sicherheits-$56,972,248-$60,423,751-Konten 6,381,938 2,651,679 Anders gegenwärtig Gewinne 1,837,879 1,693,044 Fest Gewinne, Netz 2,292,083 2,215,519 Anders Gewinne 20,575 29,361 Zählen die Billigkeit der Gewinne-$67,504,723-$67,013,354-Haftungs-$1,950,511-$2,259,414-Aktionäre 65,554,212 Zusammen 64,753,940 Total Haftung und Aktionäre ` Billigkeit $67,504,723 $67,013,354 Diese Pressemitteilung beim schick-blicken enthält Aussagen. Hierin enthaltene Aussagen, die nicht Aussagen von historischer Tatsache sind, können sein vorwärts-blickend Aussagen. Wenn die Gesellschaft die Wörter benutzt `vorwegnimmt, `Pläne, `erwartet` und ähnliche Ausdrücke sie identifizieren schick-blickend Aussagen. Solche schick-aussehende Aussagen betreffen Risiken und Ungewißheiten, die die eigentlichen Ergebnisse der Gesellschaft verursachen können, Aufführung oder Leistungen, um materiell als jene ander zu sein, drückten aus oder implizierten durch das schick-blicken Aussagen. Solche Faktoren nehmen unter anderen die sich mit Erzeugnisentwicklung verbindenden Ungewißheiten auf, das Risiko, daß klinische Prozesse nicht anfangen werden, wann oder machen weiter weiter wie geplant, verbanden die Risiken und Ungewißheiten sich mit Abhängigkeit auf den Aktionen der Gesellschaft Körperschafts-, akademisch- und Anderkollaborateure und von Regierungsregulativagenturen, das Risiko daß Erzeugnisse daß aussichtsreich in frühen klinischen Prozessen aussehen demonstrieren nicht Wirksamkeit in großzügiger klinische Prozesse, die Ungewißheit von künftiger Rentabilität und andere Faktoren stellen völliger im Jahresbericht der Gesellschaft auf Form-10-K dar da das Steuerjahr den 31. Dezember beendete, 2000 und anders periodisches Einordnen mit den Sicherheiten und Austausch-Kommission, auf die Investoren verwiesen werden, für weitere Auskunft. Im besonderen kann die Gesellschaft Sie nicht versichern den ein von der ihr programmiert wird in einem kommerziellen Erzeugnis enden. Die Gesellschaft hat keine Richtlinien zu aktualisieren oder beim schick-blicken zu revidieren Aussagen, und damit sollte es nicht angenommen werden daß die Stille der Gesellschaft im Lauf der Zeit heißt daß eigentliche Ereignisse als ausgedrückt bestätigen oder sollte nicht in solchen schick-aussehenden Aussagen angedeutet werden.


LASSEN Sie Ihre MEINUNG ZÄHLEN -- Klicken Sie Hier tbutton.prnewswire.com/prn/11690X42914068-QUELLE Progenics Pharmaceuticals, Inc.


KONTAKT: Richard W. Krawiec, Ph.D., Vizepräsident, Investoren-Beziehungen und Körperschafts-Nachrichtentechniken von Progenics Pharmaceuticals, Inc. [e-mail], 914-789-2800 /Foto: www.newscom.com-/cgi-bin/prnh/20010410/PROGENICS-URL: www.progenics.com www.prnewswire.com (C) 2001 PR Newswire. Alle vorbehaltenen Rechte.
--------------------------------------------------------------------------------



Progenics Pharmaceuticals Reports First Quarter 2001 Results
Tuesday, May 15, 2001 05:06:14 AM - PR Newswire




TARRYTOWN, N.Y., May 15, 2001 /PRNewswire via COMTEX/ -- Progenics
Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations
for the quarter ended March 31, 2001.

(Logo: www.newscom.com /cgi-bin/prnh/20010410/PROGENICS )

Revenues for the quarter ended March 31, 2001 totaled $5.8 million compared to
revenues of $3.4 million for the same period in 2000. Revenues primarily reflect
payments received by the Company under its recently terminated collaboration
with Bristol-Myers Squibb Company and its on-going collaboration with F.
Hoffmann-La Roche Ltd and funding from government grants and contracts. The
Company`s expenses for the first quarter of 2001 were $5.4 million, compared to
$4.8 million for the first quarter of 2000. Net income for the first quarter of
2001 was $461,000, compared to a net loss of ($1.5 million) for the same period
in 2000. The net income per share for the first quarter of 2001 was $0.04, basic
and $0.03 diluted, compared to a net loss per share of ($0.12), basic and
diluted, for the same period of 2000. At the end of the first quarter of 2001,
Progenics had $57.0 million in cash, cash equivalents and marketable securities
compared to $60.4 million at December 31, 2000.

Progenics Pharmaceuticals, Inc., of Tarrytown, NY, is a biopharmaceutical
company focusing on the development and commercialization of products for the
treatment and prevention of viral, cancer, and other life-threatening diseases.
The Company applies its immunological expertise to develop biopharmaceuticals to
fight viral diseases, such as human immunodeficiency virus (HIV) infections, and
cancers, such as malignant melanoma and prostate cancer. The Company has
initiated Phase II clinical trials of its lead HIV product, PRO 542, a
viral-entry inhibitor. The Company is developing follow-on product candidates in
HIV infection: PRO 367 has completed a Phase I study, PRO 140 is preparing to
commence Phase I/II trials, and a lead therapeutic candidate has been selected
from a novel class of anti-HIV compounds known as sulfated CCR5 peptides. The
Company is also engaged in programs to discover and develop small-molecule HIV
therapeutics that target the fusion co-receptors of the virus and other programs
focusing on HIV attachment and fusion. The Company is developing cancer
immunotherapies based on PSMA (prostate specific membrane antigen) technology.
The Company`s most clinically advanced product, GMK, is a cancer vaccine in
Phase III clinical trials for the treatment of malignant melanoma. Progenics is
also developing a second cancer vaccine, MGV, with broad application to a
variety of cancers. The Company is also developing a novel small-molecule
antioxidant, dehydroascorbic acid (DHA), to treat stroke and other disorders.


PROGENICS PHARMACEUTICALS, INC. CONDENSED STATEMENTS OF OPERATIONS Three Months Ended March 31, 2001 2000 (Unaudited) (Unaudited) Contract research and development, grants and product sales $4,942,305 $2,346,474 Interest income 904,479 1,027,773 Total revenues 5,846,784 3,374,247 Research and development expense 3,731,045 3,457,781 General and administrative 1,058,113 996,376 Loss in joint venture 418,020 187,913 Interest expense 12,080 22,499 Depreciation and amortization 166,277 181,645 Total expenses 5,385,535 4,846,214 Net income (loss) $461,249 $(1,471,967) Net income (loss) per share - basic $0.04 $(0.12) Net income (loss) per share - diluted $0.03 $(0.12) Weighted average common shares outstanding - basic 12,313,035 12,029,069 Weighted average common shares outstanding - diluted 13,914,386 12,029,069 CONDENSED BALANCE SHEETS March 31, December 31, 2001 2000 (Unaudited) (Unaudited) Cash, cash equivalents and marketable securities $56,972,248 $60,423,751 Accounts receivable 6,381,938 2,651,679 Other current assets 1,837,879 1,693,044 Fixed assets, net 2,292,083 2,215,519 Other assets 20,575 29,361 Total assets $67,504,723 $67,013,354 Liabilities $1,950,511 $2,259,414 Stockholders` equity 65,554,212 64,753,940 Total liabilities and stockholders` equity $67,504,723 $67,013,354
This press release contains forward-looking statements. Any statements contained
herein that are not statements of historical fact may be forward-looking
statements. When the Company uses the words `anticipates,` `plans,` `expects`
and similar expressions they are identifying forward-looking statements. Such
forward-looking statements involve risks and uncertainties which may cause the
Company`s actual results, performance or achievements to be materially different
from those expressed or implied by forward-looking statements. Such factors
include, among others, the uncertainties associated with product development,
the risk that clinical trials will not commence when or proceed as planned, the
risks and uncertainties associated with dependence upon the actions of the
Company`s corporate, academic and other collaborators and of government
regulatory agencies, the risk that products that appear promising in early
clinical trials do not demonstrate efficacy in larger-scale clinical trials, the
uncertainty of future profitability and other factors set forth more fully in
the Company`s Annual Report on Form 10-K for the fiscal year ended December 31,
2000 and other periodic filings with the Securities and Exchange Commission to
which investors are referred for further information. In particular, the Company
cannot assure you that any of the their programs will result in a commercial
product. The Company does not have a policy of updating or revising
forward-looking statements, and thus it should not be assumed that the Company`s
silence over time means that actual events are bearing out as expressed or
implied in such forward-looking statements.


MAKE YOUR OPINION COUNT -- Click Here tbutton.prnewswire.com/prn/11690X42914068
SOURCE Progenics Pharmaceuticals, Inc.


CONTACT: Richard W. Krawiec, Ph.D., Vice President, Investor Relations and Corporate Communications of Progenics Pharmaceuticals, Inc., 914-789-2800, [e-mail] /Photo: www.newscom.com /cgi-bin/prnh/20010410/PROGENICS URL: www.progenics.com www.prnewswire.com
(C) 2001 PR Newswire. All rights reserved.
--------------------------------------------------------------------------------

Ist leider ein altes übersetzungsprogramm deshalb alles nochmals auf englisch.

Gruß Xedi

[Tarotangy]

@Xedi,

vielen Dank.
Hab sie schon sehr lange.

Gruß Angy

[yxcv1234]

Scheint sich ja immer noch niemand für diesen Wert zu interessieren. Gibt ja kaum Leser von diesem Thread.

Naja, wird sich ja vielleicht bald ändern. Nach wie vor forscht diese "Mediakamentenschmiede" sehr intensiv in verschiedenen Bereichen wie AIDS und Krebs und hat dabei mehrere Produkte in den Pre-Clinical-Phases II und III.
III heißt - daß sofern die letzten Tests (mit Langzeitstudie) erfolgreich verlaufen sollten - nicht mehr all zu viel Zeit vergehen sollte, bis diese neuen Präparate am Markt sind.

[yxcv1234]

Brandaktuelle News von Progenics - vielleicht hilft´s den Kurs wieder nach oben zu bringen ... (hat ja im Moment eine charttechnisch interessante Marke erreicht):

Schmerzmediakament insbes. für Krebs- und AIDS-Patienten erreicht die Forschungsstufe II B.

Hier der exakte Text:


Progenics
Progenics Pharmaceuticals, Inc.
Old Saw Mill River Road
Tarrytown, NY 10591
[phone]
Telefax: [phone]

For Immediate Release


Contact: Progenics Pharmaceuticals, Inc.
Richard W. Krawiec, Ph.D.
Vice President
Investor Relations and Corporate Communications
[phone]
email: [e-mail]


PROGENICS INITIATES PHASE IIB CLINICAL STUDY OF INVESTIGATIONAL
DRUG TO REVERSE SIDE EFFECTS OF OPIOID PAIN THERAPY


– Methylnaltrexone being tested to relieve debilitating constipation in cancer patients –
Tarrytown, NY – February 22, 2002 – Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX)
reported today that it has initiated a Phase IIb clinical trial of its investigational drug methylnaltrexone
(MNTX) for the reversal of narcotic-induced constipation, a debilitating problem for many patients
treated with opioid pain medication. These medications are frequently used to control pain associated
with advanced cancer and AIDS. MNTX is designed to reverse the side effects of opioids without
interfering with pain relief.
The clinical trial using subcutaneous doses of MNTX is being conducted with patients being
treated in a hospice setting. Patients with progressive incurable illness, who are being treated with
opioids and suffering from constipation, will be eligible for the study. Persistent constipation is a serious
problem that afflicts approximately half of all patients who receive opioid pain medication. In 14
previous clinical studies, MNTX has been observed to reverse peripheral side-effects of opioid pain
relievers such as morphine. As MNTX does not cross the blood-brain barrier, it has shown no
interference with pain control. The goal of the study is to gather more information about dosing and
tolerability of MNTX in preparation for Phase III clinical trials which are scheduled to begin later this
year.
“In the U.S., most terminally ill patients are treated with opioids to relieve suffering, but there are
no effective drugs to alleviate the side effects caused by these medicines, which can often be as
debilitating as the pain itself,” said Robert J. Israel, MD, Progenics’ Vice President of Medical Affairs.
“We are developing methylnaltrexone for serious advanced disease, because of the significant number of
patients who have an acute need for this promising supportive-care medicine.”
“We have developed a clinical plan, which we believe provides a clear path to regulatory
approval of methylnaltrexone,” said Ronald J. Prentki, Progenics’ President. “According to a recent
study in the Journal of Clinical Oncology, [December 2001] many cancer patients indicated that they are
not taking their pain medications because of the side effects of opioids. Patients would rather endure
severe pain than suffer with opioid-induced constipation. In addition to developing methylnaltrexone for
use in cancer patients, we also plan to initiate clinical studies in the post-surgical setting and for patients
who take opioids for chronic pain.”
Progenics Initiates Phase IIb Clinical Study of Investigational Drug Page 2
Progenics Pharmaceuticals, Inc. of Tarrytown, NY, is a biopharmaceutical company focusing on
the development and commercialization of innovative therapeutic products to treat the unmet medical
needs of patients with debilitating conditions and life-threatening diseases. The Company applies its
immunological expertise to develop biopharmaceuticals to fight viral diseases, such as human
immunodeficiency virus (HIV) infection, and cancers, including malignant melanoma and prostate
cancer. The Company is conducting Phase II clinical trials with methylnaltrexone, a compound designed
to block the debilitating side effects of opioid analgesics without interfering with pain palliation. The
Company has initiated Phase II clinical trials with its lead HIV product, PRO 542, a viral-entry inhibitor
and is in preclinical development with PRO 140 and other follow-on product candidates in HIV infection.
Progenics’ most clinically advanced product, GMK, is a cancer vaccine in Phase III clinical trials for the
treatment of malignant melanoma. The Company is developing cancer immunotherapies based on PSMA
(prostate specific membrane antigen) technology. Dehydroascorbic acid (DHA), a novel small-molecule
antioxidant, is the subject of preclinical studies to treat stroke and other disorders.
This press release contains forward-looking statements. Any statements contained herein that are not statements of
historical fact may be forward-looking statements. When the Company uses the words ‘anticipates,’ ‘plans,’ ‘expects’ and
similar expressions, they are identifying forward-looking statements. Such forward-looking statements involve risks and
uncertainties, which may cause the Company’s actual results, performance or achievements to be materially different from those
expressed or implied by forward-looking statements. Such factors include, among others, the uncertainties associated with
product development, the risk that clinical trials will not commence when or proceed as planned, the risks and uncertainties
associated with dependence upon the actions of the Company’s corporate, academic and other collaborators and of government
regulatory agencies, the risk that products that appear promising in early clinical trials do not demonstrate efficacy in larger-scale
clinical trials, the uncertainty of future profitability and other factors set forth more fully in the Company’s Annual Report
on Form 10-K for the fiscal year ended December 31, 2000 and other periodic filings with the Securities and Exchange
Commission to which investors are referred for further information. In particular, the Company cannot assure you that any of the
their programs will result in a commercial product. The Company does not have a policy of updating or revising forward-looking
statements, and thus it should not be assumed that the Company’s silence over time means that actual events are bearing out as
expressed or implied in such forward-looking statements.
###
Editor’s Note:
Additional information is available at http://www.progenics.com

[yxcv1234]

Der Kurs fällt weiter, aber heute werden schon wieder Neuigkeiten aus der Biotech-Schmiede verkündet, s. unten.

Chartechnisch sieht es auch interessant aus (gut oder schlecht - je nachdem wie man´s nimmt). Persönl. Meinung: Wenn die 10$-Marke halten sollte, sollte es schnell wieder Richtung 20 gehen.


Und hier die Meldung:



Progenics Selects Clinical Candidate for HIV Therapy: Humanized PRO 140 Antibody Blocks Viral Entry
2/26/2002 - 5:00:00 AM

- Novel small-molecule inhibitors of CCR5-mediated HIV entry are also identified -

SEATTLE, Feb 26, 2002 /PRNewswire-FirstCall via COMTEX/ --Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) has selected a humanized form of its PRO 140 antibody for clinical testing as a promising new HIV therapy. PRO 140 works by a novel mechanism not exploited by any of the currently approved HIV agents: it blocks CCR5, a receptor on the cell surface that the human immunodeficiency virus (HIV) utilizes to enter and infect cells. Unlike its mouse-based predecessor, humanized PRO 140 is designed to be suitable for repeat dosing in humans. Humanization of the PRO 140 monoclonal antibody was accomplished under a collaborative agreement with Protein Design Labs, Inc. (Nasdaq: PDLI), Fremont, CA. Progenics also reported the identification of small-molecule CCR5 inhibitors with novel antiviral properties, which were identified in collaboration with the Roche Group, headquartered in Basel, Switzerland, using Progenics` proprietary approach to identifying CCR5 inhibitors. Both sets of findings were presented today at the 9th Conference on Retroviruses and Opportunistic Infections in Seattle.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010410/PROGENICS )

"In the laboratory, humanized PRO 140 has demonstrated potent inhibitory activity against diverse HIV isolates," said William C. Olson, Ph.D., Vice President, Research & Development at Progenics and coauthor of the presentation. "In side-by-side testing, humanized PRO 140 reproduced the compelling antiviral profile of the original mouse antibody, but in a form suitable for chronic administration. PRO140 may play an important role in HIV therapy, especially in patients who are resistant to current anti-retrovirals and in need of new therapeutic options. We look forward to rapidly advancing this innovative product into clinical testing next year."

Humanized PRO 140 is designed to be non-immunogenic and thus may be suitable for long-term therapy of HIV-infected individuals. Progenics presented results that the new humanized PRO 140 antibody is capable of blocking replication of multiple strains of HIV in laboratory assays. In a mouse model of HIV infection, Progenics had previously reported that mouse PRO 140 was highly effective in controlling HIV replication, with viral levels reduced to undetectable levels in all animals treated.

CCR5 is a human protein that resides on the surface of certain immune system cells. CCR5 normally acts as a receptor for chemokines, which are molecules involved in inflammation. However, CCR5 also serves as a portal of entry for HIV into immune cells that also express CD4, which mediates the initial attachment of the virus to the cell. Certain individuals who do not express a functional CCR5 protein are highly resistant to infection with HIV, and provide clinical proof-of-concept for CCR5 inhibitors. PRO 140 is a monoclonal antibody that binds to a portion of the CCR5 receptor and blocks HIV entry while having no apparent effect on the normal function of CCR5.

Small molecules are designed to block HIV entry, not normal CCR5 receptor function

In a separate poster presentation, scientists from Progenics described the properties of a novel series of compounds discovered under its research collaboration with the Roche Group to develop orally active, small-molecule inhibitors of CCR5. The new series of compounds potently and specifically blocked HIV entry in multiple laboratory studies. In addition, these compounds had little or no effect on the normal function of CCR5.

"The unique activity profile of these compounds derives from our novel approach to developing CCR5 inhibitors and provide proof that this approach may be useful in identifying new antiretroviral agents," said Bryan M. O`Hara, Ph.D., Director, Virology at Progenics and co-author of the presentation.

Progenics Pharmaceuticals, Inc. of Tarrytown, NY, is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The Company applies its immunological expertise to develop biopharmaceuticals to fight viral diseases, such as human immunodeficiency virus (HIV) infection, and cancers, including malignant melanoma and prostate cancer. The Company is conducting Phase II clinical studies with methylnaltrexone, a compound designed to block the debilitating side effects of opioid analgesics without interfering with pain palliation. The Company has initiated Phase II clinical trials with its lead HIV product, PRO 542, a viral-entry inhibitor and is in preclinical development with PRO 140 and other follow-on product candidates in HIV infection. Progenics` most clinically advanced product, GMK, is a cancer vaccine in Phase III clinical trials for the treatment of malignant melanoma. The Company is developing cancer immuno therapies based on PSMA (prostate specific membrane antigen) technology. Dehydro ascorbic acid (DHA), a novel small-molecule antioxidant, is the subject of preclinical studies to treat stroke and other disorders.

This press release contains forward-looking statements. Any statements contained herein that are not statements of historical fact may be forward-looking statements. When the Company uses the words "anticipates," "plans," "expects" and similar expressions, they are identifying forward-looking statements. Such forward-looking statements involve risks and uncertainties, which may cause the Company`s actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. Such factors include, among others, the uncertainties associated with product development, the risk that clinical trials will not commence when or proceed as planned, the risks and uncertainties associated with dependence upon the actions of the Company`s corporate, academic and other collaborators and of government regulatory agencies, the risk that products that appear promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the uncertainty of future profitability and other factors set forth more fully in the Company`s Annual Report on Form 10-K for the fiscal year ended December 31, 2000 and other periodic filings with the Securities and Exchange Commission to which investors are referred for further information. In particular, the Company cannot assure you that any of the their programs will result in a commercial product. The Company does not have a policy of updating or revising forward-looking statements, and thus it should not be assumed that the Company`s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements.

[yxcv1234]

Der Wert zieht wieder an. Vielleicht auch wegen IMCLONE.

Wer mal den Chart von Progenics anschauen sollte, vielleicht zusammen mit den RSI-Linien (Relative Stärke Index) und dem MACD-Indikator wird sehen, daß Progenics als erstes locker noch bis 19-20 € laufen könnte, was lockere 20-30% Gewinn vom aktuellen Kurs aus gesehen bedeutet.

Längerfrisitg gesehen - schwer zu beurteilen. Ist abhängig davon, wie die Tests mit den neuen Medikamenten zur Behandlung von Krebs, Aids und anderem verlaufen.
Aber nichts ist unmöglich - siehe jetzt wieder IMCLONE (30% Aktiengewinn an einem Tag).

So long.

[yxcv1234]

Fernsehtipp:

Heute (8.3.) soll um ca. 22.20 Uhr auf Bloomberg-TV Progenics charttechnisch beleuchtet werden. Insbesondere über dem Moneyflow von institutionellen Investoren sprich Fonds.

Sendung wird übrigens am Sonnabend (9.3.) ca. 15.20 Uhr wiederholt.

Also Einschalten !!!

[yxcv1234]

Die Brandaktuellen Zahlen für 2001 liegen nun vor.
Für den, den es interessiert hier der Report:

"March 29, 2002
PROGENICS PHARMACEUTICALS INC (PGNX)
Annual Report (SEC form 10-K)
Item 7. Management`s Discussion and Analysis of Financial Condition and Results of Operations
Overview
Progenics is a biopharmaceutical company focusing on the development and commercialization of innovative products to address the unmet medical needs of patients with debilitating conditions and life-threatening diseases. We commenced principal operations in late 1988 and since that time have been engaged primarily in research and development efforts, development of our manufacturing capabilities, establishment of corporate collaborations and raising capital. In order to commercialize the principal products that we have under
development, we will need to address a number of technological challenges and comply with comprehensive regulatory requirements. Accordingly, it is not possible to predict the amount of funds that will be required or the length of time that will pass before we receive revenues from sales of any of these products. To date, product sales have consisted solely of limited revenues from the sale of research reagents. We expect that sales of research reagents in the future will not significantly increase over current levels. Our other sources of revenues through December 31, 2001 have been payments received under our collaboration agreements, research grants and contracts related to our cancer and HIV programs and interest income.
To date, a majority of our expenditures have been for research and development activities. We expect that our research and development expenses will increase significantly as our programs progress and we make filings for related regulatory approvals. With the exception of the years ended December 31, 1997 and 1998, we have had recurring losses and had, at December 31, 2001, an accumulated deficit of approximately $25,519,000. We will require additional funds to complete the development of our products, to fund the cost of clinical trials and to fund operating losses that are expected to continue for the foreseeable future. We do not expect our products under development to be commercialized in the near future.
Results of Operations
Years Ended December 31, 2000 and 2001
Contract research and development revenue decreased from $7,941,000 in 2000 to $5,115,000 in 2001. The decrease was primarily attributable to: (i) a reduction of contract research and development funding received by the Company after the Company and Bristol-Myers Squibb Company ("BMS") mutually terminated our collaboration agreement in May 2001, and (ii) the expiration of one of the Company`s contracts with the NIH in 2001. The Company also received a non- recurring payment of approximately $9,852,000 from BMS in connection with the termination of the BMS Agreement. As a result of the termination of the BMS Agreement, the Company will receive no additional payments from BMS. Revenues from research grants increased from $1,835,000 in 2000 to $3,725,000 in 2001. The increase resulted from the funding of a greater number of grants in 2001. Sales of research reagents decreased from $46,000 in 2000 to $43,000 in 2001 resulting from decreased orders for such reagents during 2001. Interest income decreased from $4,127,000 in 2000 to $3,348,000 in 2001 as cash available for investing remained relatively constant and interest rates decreased year over year.
Research and development expenses increased from $13,075,000 in 2000 to $14,501,000 in 2001. The increase was principally due to an increase in headcount, related laboratory supplies and additional rent for new laboratory space as the Company expanded its research and development programs to include MNTX (methylnaltrexone).
General and administrative expenses increased from $5,042,000 in 2000 to 6,499,000 in 2001. The increase was principally due to an increase in legal expenses related to the Company`s intellectual property filings and prosecutions, headcount and additional rent for new office space to accommodate growth.
Loss in joint venture increased from $945,000 in 2000 to $2,225,000 in 2001. The increase was primarily due to the growth and acceleration of the joint venture`s development programs to develop in vivo immunotherapies for prostate cancer and the costs of licensing transactions.
Interest expense decreased from $95,000 in 2000 to $49,000 in 2001. The decrease was principally due to the recognition of interest expense as the Company discounted future capital contributions to the joint venture which decreased in 2001 and reduced capital lease obligations in 2001.
Our net loss was $5,917,000 in 2000 compared to net loss of $1,898,000 in 2001.
Years Ended December 31, 1999 and 2000
Contract research and development revenue decreased from $14,867,000 in 1999 to $7,941,000 in 2000. The decrease was the result of receiving milestone payments in 1999 in connection with our collaboration with BMS. No such payments were received in 2000. Reimbursement of clinical development costs during 2000 remained at 1999 levels. Revenues from research grants increased from $1,106,000 in 1999 to $1,836,000 in 2000. The increase resulted from the funding of a greater number of grants in 2000. Sales of research reagents increased from $40,000 in 1999 to $45,000 in 2000 resulting from increased orders for such reagents during 2000. Interest
income increased from $1,440,000 in 1999 to $4,127,000 in 2000 as cash available for investing increased due the Company`s public offering which closed in November 1999.
Research and development expenses increased from $11,227,000 in 1999 to $13,075,000 in 2000. The increase was principally due to an increase in headcount, related laboratory supplies and additional rent for new laboratory space as the Company expanded its research and development programs to include PSMA and DHA and additional costs of manufacturing PRO 542.
General and administrative expenses increased from $3,866,000 in 1999 to $5,042,000 in 2000. The increase was principally due to an increase in headcount and additional rent for new office space to accommodate growth.
Loss in joint venture decreased from $2,047,000 in 1999 to $945,000 in 2000. The decrease was primarily due to the expensing of a license fee with respect to intellectual property in 1999. Research activities on PSMA commenced in the second half of 1999.
Interest expense decreased from $112,000 in 1999 to $95,000 in 2000. The decrease was principally due to the recognition of interest expense as the Company discounted future capital contributions to the joint venture which decreased in 2000.
Our net loss was $496,000 in 1999 compared to net loss of $5,917,000 in 2000.
Liquidity and Capital Resources
We have funded our operations since inception primarily through private placements of equity securities, loans that were subsequently converted into equity securities, a line of credit that was repaid and terminated, payments received under collaboration agreements, such as those with BMS and Roche, two public offerings of common stock, funding under government research grants and contracts, interest on investments, and the proceeds from the exercise of outstanding options and warrants. In May 2001 the Company and BMS mutually agreed to terminate our cancer vaccine collaborative development agreement, pursuant to which we regained all rights to the products and received a non- recurring payment of approximately $9,852,000 from BMS. As a result of the termination of the BMS Agreement, the Company will receive no additional payments from BMS.
In November 1997, we sold 2,300,000 shares of common stock in our initial public offering. After deducting underwriting discounts and commissions and other expenses, we received net proceeds of $16,015,000. In November 1999, we completed an additional public offering of 2,300,000 shares of common stock and received net proceeds, after underwriting discounts and commissions and other expenses, of $40,584,000. The net proceeds from both offerings were invested in short-term, interest bearing investment grade securities pending further application.
At December 31, 2001, we had cash, cash equivalents and marketable securities, including non-current portion, totaling approximately $61,877,000 compared with approximately $60,424,000 at December 31, 2000. Our facility lease has been extended to June 2005. In connection with the extended facility lease, we expended approximately $888,000 for equipment and leasehold improvements during 2001. In addition, we are obligated, under the terms of our joint venture with Cytogen Corporation to fund research and development of up to $3.0 million prior to the commencement of sharing these expenses with Cytogen. During the fourth quarter of 2001, we were required to pay $650,000 as our share of the joint venture contribution, of which $150,000 was paid in December 2001 and $500,000 was paid in January 2002. We and Cytogen reached a mutually satisfactory agreement with respect to the resolution of a dispute related to the timely reacquisition on behalf of the Joint Venture of certain rights from a third party, which we had reported last year and which could have reduced our initial funding obligation by $500,000.
Our total expenses for research and development from inception through December 31, 2001 have been approximately $71.0 million. We currently have major research and development programs investigating cancer and human immunodeficiency virus-related diseases ("HIV"), for which we are or have licensed technology and collaborated with other pharmaceutical and biotechnology companies. In addition, we are conducting several smaller projects in the areas of stroke and pain. For various reasons, many of which are outside of our control, including the early stage of our programs, the timing and results of our clinical trials and our dependence on third parties, we cannot estimate the total remaining costs to be incurred and timing to complete our research and
development programs. For the years ended December 31, 2001, 2000 and 1999, research and development costs incurred were as follows:
Years Ended December 31,
------------------------
1999 2000 2001
----- ----- -----
(in $ million)
Cancer....................................................... $ 6.8 $ 5.7 $ 4.2
HIV.......................................................... 3.9 6.9 9.8
Other programs............................................... .5 .5 .5
----- ----- -----
Total....................................................... 11.2 13.1 14.5
We believe that our existing capital resources should be sufficient to fund operations at least through 2003. However, this is a forward-looking statement based on our current operating plan and the assumptions on which it relies. There could be changes that would consume our assets before such time. We will require substantial funds to conduct research and development activities, preclinical studies, clinical trials and other activities relating to the commercialization of any potential products. In addition, our cash requirements may vary materially from those now planned because of results of research and development and product testing, changes in existing relationships with, or new relationships with, licensees, licensors or other collaborators, changes in the focus and direction of our research and development programs, competitive and technological advances, the cost of filing, prosecuting, defending and enforcing patent claims, the regulatory approval process, manufacturing and marketing and other costs associated with the commercialization of products following receipt of regulatory approvals and other factors. We have no committed external sources of capital and, as discussed above, expect no significant product revenues for a number of years as it will take at least that much time, if ever, to bring our products to the commercial marketing stage. We may seek additional financing, such as through future offerings of equity or debt securities or agreements with corporate partners and collaborators with respect to the development of our technology, to fund future operations. We cannot assure you, however, that we will be able to obtain additional funds on acceptable terms, if at all. We have no off- balance sheet arrangements and do not guarantee the obligations of any other entity.
In connection with our funding requirements, the following table summarizes our contractual obligations as of December 31, 2001, for future operating lease payments and payments for licensing, corporate collaboration and service agreements:
Payments Due by
Period
---------------
Less than 1 to 3 4 to 5 Greater than
Total one year years years 5 years
----- --------- ------ ------ ------------
(in $ millions)
Operating leases........................................................... $ 2.7 $0.7 $1.6 $0.4
Licensing, collaboration and service agreements (1)........................ 22.7 1.2 5.4 6.3 9.8
- (1) Assumes attainment of milestones covered under each agreement.
Critical Accounting Policies
Revenue Recognition
We recognize revenue from contract research and development as we perform services, provided a contractual agreement exists, the contract price is fixed or determinable, and our collection of the resulting receivable is probable. In situations where we receive payment in advance of the performance of services, these amounts are deferred and recognized as revenue as we perform the related services. Non-refundable fees, including payments we receive for services, up-front licensing fees and milestone payments are recognized as revenue based on the percentage of costs incurred to date, estimated costs to complete and total expected contract revenue. However, the revenue we recognize is limited to the amount of non-refundable fees received. Non- refundable fees that we receive in consideration for granting collaborators the right to license product candidates developed by us are recognized as revenue on a straight-line basis over the term of the underlying agreements. With regard to our revenues from non-refundable fees, changes in estimates of our costs to complete could have a material impact on the revenues we recognize.
In connection with the formation of the equally-owned joint venture in the form of a partnership (the "Partnership") between us and Cytogen Corporation (the "Partners"), we have funded the first $3.0 million of research and development costs incurred on behalf of the Partnership. Prior to reaching $3.0 million of such costs, we recognized reimbursements on a net basis and did not recognize any revenue from the Partnership. Subsequent to having funded $3.0 million of research and development costs, in the fourth quarter of 2001, both Partners are required to fund the Partnership to support ongoing research and development efforts conducted by us on behalf of the Partnership. Accordingly, following $3.0 million of funding, we, acting as a principal, recognize payments for research and development as revenue. We are the primary obligor responsible for providing the service, by conducting research and development, desired by the Partnership, including the acceptability of the research and development services and we have established the amounts we will be reimbursed for the services by selecting the subcontractors and suppliers we employ in conducting the research and development for the Partnership.
Clinical Trial Expenses
Clinical trial expenses, which are included in research and development expenses, represent obligations resulting from our contracts with various clinical research organizations in connection with conducting clinical trials for our product candidates. Such costs are expensed based on the expected total number of patients in the trial, the rate at which the patients enter the trial and the period over which the clinical research organizations are expected to provide services. We believe that this method best approximates the efforts expended on a clinical trial with the expenses we record. We adjust our rate of clinical expense recognition if actual results differ from our estimates.
Impact of the Adoption of Recently Issued Accounting Standards
In July 2001, the Financial Accounting Standards Board issued Statement No. 141, "Business Combinations," and Statement No. 142, "Goodwill and Other Intangible Assets." FAS 141 requires that all business combinations be accounted for under the purchase method and that certain acquired intangible assets in a business combination be recognized as assets apart from goodwill. FAS 142 requires that ratable amortization of goodwill and certain intangible assets be replaced with periodic tests of the goodwill`s impairment and that other intangible assets be amortized over the useful lives. FAS 141 is effective for all business combinations initiated after June 30, 2001. The provisions of MS 142 will be effective for fiscal years beginning after December 15, 2001 and will be adopted by the Company in 2002. The Company does not expect the adoption of FAS 141 and 142 to have a material impact on its financial statements.
In July 2001, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 143, "Accounting for Obligations Associated with Retirement of Long-Lived Assets." The objective of FAS 143 is to provide accounting guidance for legal obligations associated with the retirement of tangible long-lived assets. The retirement obligations included with the scope of FAS 143 are those that an entity cannot avoid as a result of either the acquisition, construction or normal operation of a long-lived asset. Components of larger systems also fall under FAS 143, as well as intangible long-lived assets with indeterminable lives. FAS 143 is require to be adopted on January 1, 2003. The Company does not expect the adoption of FAS 143 to have any material impact on its financial statements.
The Financial Accounting Standards Board issued FASB Statement No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets." The objectives of FAS 144 are to address significant issues relating to the implementation of FASB Statement No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of," and to develop a single accounting model, based on the framework established in FAS 121, for long-lived assets to be disposed of by sale, whether previously held and used or newly acquired. The provisions of FAS 144 are effective for financial statements issued for fiscal years beginning after December 15, 2001. The Company does not expect the adoption of FAS 144 to have any material impact on its financial statements."